As a recognized leader in excipient solutions for inhalation, DFE Pharma supports the pharmaceutical industry in developing Dry Powder Inhalation (DPI) formulations with its exceptional expertise. We are at the forefront of excipient innovation, with our lactose-based excipients featured in 80% of dry powder inhalers globally. Furthermore, with our BioHale® platform we also provide a solution for carrier-free formulations, supporting the future of inhaled therapies.

Our high-quality, customizable excipients enable robust formulation development, ensuring optimal DPI performance through a precise particle size distribution (PSD). With our formulation expertise and three dedicated inhalation production sites, we provide a unique foundation for advanced pharmaceutical applications.

By partnering with DFE Pharma, you gain access to premium excipients and our state-of-the-art analytical lab at the Closer to the Formulator (C2F) Center, designed to optimize formulations. Complementing this, our strategic partnerships with STERLING S.p.A. (API particle engineering) and HARRO HÖFLIGER (process and filling equipment) accelerate inhalation drug development, offering comprehensive support at every stage.